Skip to main content

 8YKG | pdb_00008ykg

Structure of SARS-CoV-2 spike glycoprotein in complex with NT-108 scFv (1-up state)


Experimental Data Snapshot

  • Method: ELECTRON MICROSCOPY
  • Resolution: 3.28 Å
  • Aggregation State: PARTICLE 
  • Reconstruction Method: SINGLE PARTICLE 

Starting Model: experimental
View more details

wwPDB Validation 3D Report Full Report

Validation slider image for 8YKG

This is version 1.1 of the entry. See complete history. 

Literature

Structural and virological identification of neutralizing antibody footprint provides insights into therapeutic antibody design against SARS-CoV-2 variants.

Anraku, Y., Kita, S., Onodera, T., Sato, A., Tadokoro, T., Ito, S., Adachi, Y., Kotaki, R., Suzuki, T., Sasaki, J., Shiwa-Sudo, N., Iwata-Yoshikawa, N., Nagata, N., Kobayashi, S., Kazuki, Y., Oshimura, M., Nomura, T., Sasaki, M., Orba, Y., Suzuki, T., Sawa, H., Hashiguchi, T., Fukuhara, H., Takahashi, Y., Maenaka, K.

(2025) Commun Biol 8: 483-483

  • DOI: https://doi.org/10.1038/s42003-025-07827-0
  • Primary Citation Related Structures: 
    8YK4, 8YKG, 8YKH

  • PubMed Abstract: 

    Medical treatments using potent neutralizing SARS-CoV-2 antibodies have achieved remarkable improvements in clinical symptoms, changing the situation for the severity of COVID-19 patients. We previously reported an antibody, NT-108 with potent neutralizing activity. However, the structural and functional basis for the neutralizing activity of NT-108 has not yet been understood. Here, we demonstrated the therapeutic effects of NT-108 in a hamster model and its protective effects at low doses. Furthermore, we determined the cryo-EM structure of NT-108 in complex with SARS-CoV-2 spike. The single-chain Fv construction of NT-108 improved the cryo-EM maps because of the prevention of preferred orientations induced by Fab orientation. The footprints of NT-108 illuminated how escape mutations such as E484K evade from class 2 antibody recognition without ACE2 affinity attenuation. The functional and structural basis for the potent neutralizing activity of NT-108 provides insights into the rational design of therapeutic antibodies.


  • Organizational Affiliation: 
    • Laboratory of Biomolecular Science, and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.

Macromolecule Content 

  • Total Structure Weight: 456.96 kDa 
  • Atom Count: 26,426 
  • Modeled Residue Count: 3,353 
  • Deposited Residue Count: 4,099 
  • Unique protein chains: 2

Macromolecules

Find similar proteins by:|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
Spike glycoprotein
A, B, C
1,199Severe acute respiratory syndrome coronavirus 2Mutation(s): 9 
Gene Names: S, 2
UniProt
Find proteins for P0DTC2 (Severe acute respiratory syndrome coronavirus 2)
Explore P0DTC2 
Go to UniProtKB:  P0DTC2
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP0DTC2
Glycosylation
Glycosylation Sites: 7Go to GlyGen: P0DTC2-1
Sequence Annotations
Expand
Reference Sequence
Find similar proteins by:|  3D Structure
Entity ID: 2
MoleculeChains  Sequence LengthOrganismDetailsImage
NT-108 scFvD,
E [auth F]
251Homo sapiensMutation(s): 0 
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
Sequence Annotations
Expand
Reference Sequence

Oligosaccharides

Help  
Entity ID: 3
MoleculeChains Length2D Diagram GlycosylationD Interactions
2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranoseF [auth E],
G
2N-Glycosylation
Glycosylation Resources
GlyTouCan: G42666HT
GlyCosmos: G42666HT
GlyGen: G42666HT

Small Molecules

Ligands 1 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
NAG

Query on NAG



Download:Ideal Coordinates CCD File
H [auth A]
I [auth A]
J [auth A]
K [auth A]
L [auth A]
H [auth A],
I [auth A],
J [auth A],
K [auth A],
L [auth A],
M [auth A],
N [auth A],
O [auth B],
P [auth B],
Q [auth B],
R [auth B],
S [auth B],
T [auth B],
U [auth C],
V [auth C],
W [auth C],
X [auth C],
Y [auth C],
Z [auth C]
2-acetamido-2-deoxy-beta-D-glucopyranose
C8 H15 N O6
OVRNDRQMDRJTHS-FMDGEEDCSA-N

Experimental Data & Validation

Experimental Data

  • Method: ELECTRON MICROSCOPY
  • Resolution: 3.28 Å
  • Aggregation State: PARTICLE 
  • Reconstruction Method: SINGLE PARTICLE 
EM Software:
TaskSoftware PackageVersion
MODEL REFINEMENTPHENIX1.19.2
RECONSTRUCTIONRELION3.1

Structure Validation

View Full Validation Report



Entry History 

& Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Japan Agency for Medical Research and Development (AMED)JapanJP17am0101093
Japan Agency for Medical Research and Development (AMED)JapanJP20ae0101047
Japan Agency for Medical Research and Development (AMED)JapanJP21fk0108463
Japan Agency for Medical Research and Development (AMED)JapanJP22ama121037
Japan Society for the Promotion of Science (JSPS)JapanJP20H05873
Japan Agency for Medical Research and Development (AMED)JapanJP223fa627005
Japan Agency for Medical Research and Development (AMED)JapanJP223fa627009
Japan Agency for Medical Research and Development (AMED)JapanJP23jf0126002

Revision History  (Full details and data files)

  • Version 1.0: 2025-03-12
    Type: Initial release
  • Version 1.1: 2026-11-18
    Changes: Data collection, Database references